Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer38

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer7

Views

Views
July 20250
August 20250
September 20252
October 20250
November 20253
December 20250
January 20262
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
Brazil2
Finland2
 

Top cities views

Views
Helsinki2
Dallas2
Canaã dos Carajás1
Franca1